Genetic modification of T cells for immunotherapy

Author： Berger Carolina Berger Michael Feng Junli Riddell Stanley R

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.7, Iss.8, 2007-08, pp. : 1167-1182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Adoptive transfer of antigen-specific T cells is a promising approach for preventing progressive viral infections in immunosuppressed hosts. By contrast, effective T-cell therapy of malignant disease has proven to be much more difficult to achieve. This, in part, reflects the difficulty of isolating high avidity T cells specific for tumor-associated antigens, many of which are self-antigens that have induced some level of tolerance in the host. Even when tumor-reactive T cells can be isolated, the ability of these cells to survive in vivo and traffic to tumor sites is often impaired. Additionally, most tumors employ multiple mechanisms to escape T-cell recognition, including interference in antigen presentation, secretion of inhibitory factors and recruitment of regulatory or immunosuppressive cells. The genetic modification of T cells prior to transfer provides a potential means to overcome many of these obstacles and enhance the efficacy of T-cell therapy. This review article discusses the rationale for genetic modification of T cells, the critical steps involved in gene transfer, and potential advantages and disadvantages of strategies that are now being examined to engineer improved effector T cells for the treatment of human infectious and malignant disease.

Related content

T regulatory cells as an immunotherapy for transplantation

By Albert Michael H Anasetti Claudio Yu Xue-Zhong

Expert Opinion on Biological Therapy, Vol. 6, Iss. 4, 2006-04 ,pp. : 315-324 (10)

Informa Healthcare

Access to resources Recommend Favorite

Immunoregulatory T cells in cancer immunotherapy

By Morse Michael A Clay Timothy M Mosca Paul Lyerly H Kim

Expert Opinion on Biological Therapy, Vol. 2, Iss. 8, 2002-12 ,pp. : 827-834 (8)

Informa Healthcare

Access to resources Recommend Favorite

Bispecific antibodies engage T cells for antitumor immunotherapy

By Choi Bryan D Cai Mingqing Bigner Darell D Mehta Ankit I Kuan Chien-Tsun Sampson John H

Expert Opinion on Biological Therapy, Vol. 11, Iss. 7, 2011-07 ,pp. : 843-853 (11)

Informa Healthcare

Access to resources Recommend Favorite

Generation and genetic modification of induced pluripotent stem cells

By Schambach Axel Cantz Tobias Baum Christopher Cathomen Toni

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1089-1103 (15)

Informa Healthcare

Access to resources Recommend Favorite

Adoptive T cell immunotherapy for cytomegalovirus

By Peggs Karl S

Expert Opinion on Biological Therapy, Vol. 9, Iss. 6, 2009-06 ,pp. : 725-736 (12)

Informa Healthcare

Access to resources Recommend Favorite